Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Daisuke Yabe & Yutaka Seino. (2016) Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety 15:2, pages 249-264.
Read now
Read now
André J Scheen. (2015) Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 11:6, pages 1005-1020.
Read now
Read now
André J Scheen. (2015) Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety 14:4, pages 505-524.
Read now
Read now
Kohei Kaku, Mikiko Mori, Tatsuhiro Kanoo, Masafumi Katou & Yutaka Seino. (2014) Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase. Expert Opinion on Pharmacotherapy 15:15, pages 2121-2130.
Read now
Read now
Articles from other publishers (6)
Ramji Rathod, Faraat Ali, Amrish Chandra, Robin Kumar, Meenakshi Dahiya & Gyanendra Nath Singh. (2021) Simultaneous Determination of Alogliptin, Linagliptin, Saxagliptin, and Sitagliptin in Bulk Drug and Formulation by UPLC Q-TOF-MS. Current Pharmaceutical Analysis 17:1, pages 95-105.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:12, pages 1225-1238.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:10, pages 999-1024.
Crossref
Crossref
Koji Akita, Kikuo Isoda, Kazunori Shimada & Hiroyuki Daida. (2015) Dipeptidyl‐Peptidase‐4 Inhibitor, Alogliptin, Attenuates Arterial Inflammation and Neointimal Formation After Injury in Low‐Density Lipoprotein (LDL) Receptor‐Deficient Mice. Journal of the American Heart Association 4:3.
Crossref
Crossref
Hiromi HamamotoKoji NakanishiMitsuhiko Noda. (2015) Analyzing the Factors Contributing to Withdrawal from Insulin Therapy following Additional Administration of Alogliptin: Retrospective Study after Removing Glucotoxicity with Insulin. Japanese Clinical Medicine 6, pages JCM.S27202.
Crossref
Crossref
André J. Scheen. (2014) Alogliptin: Concern About Hepatotoxicity?. Clinical Pharmacokinetics 53:11, pages 1057-1059.
Crossref
Crossref